Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-inflammatory therapeutics - Omeros Corporation

Drug Profile

Research programme: anti-inflammatory therapeutics - Omeros Corporation

Alternative Names: anti MASP-3 antibody - Omeros Corporation; anti-MASP-2 monoclonal antibody - Omeros Corporation; MASP-2 therapeutics - Omeros Corporation; MASP-3 therapeutics - Omeros Corporation; OMS 906

Latest Information Update: 27 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Omeros Corporation
  • Class Anti-inflammatories; Eye disorder therapies; Monoclonal antibodies; Small molecules
  • Mechanism of Action Mannose binding protein associated serine protease inhibitors; MASP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute kidney injury; Age-related macular degeneration; Haemolytic uraemic syndrome; Inflammation; Myocardial reperfusion injury; Paroxysmal nocturnal haemoglobinuria; Reperfusion injury; Stroke

Most Recent Events

  • 25 Sep 2019 Preclinical trials in Acute kidney injury in USA (Intraperitoneal)
  • 08 Aug 2019 Omeros Corporation plans a clinical trial for MASP-2 inhibitors by mid of 2021 (SC) (PO)
  • 08 Aug 2019 Omeros Corporation plans a clinical trial for OMS 906 for Paroxysmal nocturnal haemoglobinuria in first half of 2020 (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top